Zealand Pharma A/S, a biotech company, designs and develops novel peptide medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of adults with type 2 diabetes under the Lyxumia name. It also develops LixiLan, a single injection combination of lixisenatide and insulin glargine, which completed Phase III clinical trial for type 2 diabetes; and Elsiglutide, a GLP-2 peptide receptor agonist that is in Phase IIb clinical trial for the treatment of chemotherapy-induced diarrhea with colorectal cancer. In addition, the company develops Glucagon/GLP-1 dual agonist, which is in preclinical development to treat diabetes and/or obesity; a drug candidate that is in preclinical development for the treatment of cardio-metabolic diseases; and ZP4207, which is in Phase II clinical trial to treat hypoglycemia, as well as in Phase I clinical trial for hypoglycemia management in diabetes. Further, it develops ZP1848, a long-acting GLP-2 analogue that is in Phase II clinical trial for the treatment of short bowel syndrome; and ZP2929, a once-daily dual acting glucagon/GLP-1 receptor agonist, which is in Phase I clinical trial for patients with type 2 diabetes and/or obesity, as well as various therapeutic peptides in preclinical development. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.
zealand pharma a/s (ZEAL:Copenhagen)
Phone: 45 88 77 36 00
Fax: 45 88 77 38 98www.zealandpharma.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for ZEAL.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ZEALAND PHARMA A/S, please visit www.zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.